Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Patent Litigation
-
By Sherri Oslick — Last week, GlaxoSmithKline and Cypress Pharmaceutical filed a joint stipulation of dismissal in their pending lawsuit over generic Zantac® syrup. The suit was filed on June 25, 2007 in the Southern District of New York (see our previous report). Under the terms of the settlement, GSK has agreed not…
-
By Kevin E. Noonan — Once recombinant cells were deemed to constitute patentable subject matter by the U.S. Supreme Court in Diamond v. Chakrabarty, fundamental properties of such cells began to pose new challenges to traditional patent law concepts. One such property is that these cells were capable of replicating to produce copies…
-
By Donald Zuhn — On December 21, 2007, Illumina, Inc. announced that the U.S. Patent and Trademark Office had ordered the reexamination of U.S. Patent Nos. 6,355,432; 6,646,243; 5,545,531; and 5,795,716. The patents ordered into reexamination constitute four of the five patents that Affymetrix, Inc. asserted against Illumina in an infringement action filed…
-
By Robert Dailey — Life sciences companies Invitrogen and Genetic Applications (GA) have settled the patent infringement suit that GA filed last year alleging infringement of U.S. Reissued Patent No. RE39,220. The ‘220 patent is directed to methods of transplanting DNA into a eukaryotic genome to yield hematopoietic cell lines. These cell lines…
-
By Robert Dailey — Just two years ago, the world of patent law (and maybe even Michael Crichton) waited for the Supreme Court to reconsider the standard for patentable subject matter – at least with respect to process claims. The Supremes had granted cert. on the following question: "Whether a patent instructing a…
-
By Sherri Oslick — Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, and Watson Pharmaceuticals, Inc., have announced that they have reached a settlement agreement in Biovail’s lawsuit against Andrx Pharmaceuticals, Inc., a subsidiary of Watson. The lawsuit was filed following a paragraph IV certification as part of Andrx’s filing of an…
-
By Kevin E. Noonan — Gene Quinn from the PLI blog reports today that Judge Cacheris has set the briefing schedule for summary judgment motions in the challenge to the claims and continuation rules enjoined by the Court on October 31st (see Patent Docs report). All parties must file summary judgment motions and…
-
By Baltazar Gomez — Last month, Astellas Pharma Inc., King Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd. announced that U.S. subsidiaries of Astellas, along with Item Development AB and King have signed settlement agreements with respect to U.S. Patent Nos. 5,731,296 and 5,070,877. The lawsuits involving the ‘296 and ‘877 patents were filed…
-
By Sherri Oslick — Ranbaxy Laboratories, Astellas Pharma US, Inc., and Boehringer Ingelheim Corporation have announced their agreement to enter into a joint stipulation of dismissal without prejudice in their lawsuit over FLOMAX® (tamsulosin hydrochloride, used to treat benign prostatic hyperplasia). Under the terms of the settlement agreement, Ranbaxy will have the opportunity…
-
By Robert Dailey — AstraZeneca and Israeli generic drug manufacturer Dexcel Pharma recently settled litigation involving the 20 mg delayed-release formulation of omeprazole (Prilosec®). Under the agreement, Dexcel and its partner, Perrigo Company, will have the exclusive marketing rights to the store-branded OTC version of omeprazole. In May 2006, AstraZeneca had filed suit…
Patent Docs 